Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain

The objective of this international, multicenter, open-label trial was to assess the efficacy and safety of up to 12 months of therapy with transdermal therapeutic system (TTS) fentanyl in patients (n = 532) with chronic noncancer pain. The trial was completed by 301 (57%) of the patients. The main...

Full description

Saved in:
Bibliographic Details
Published in:The journal of pain 2001-08, Vol.2 (4), p.197-204
Main Authors: Milligan, Keith, Lanteri-Minet, Michel, Borchert, Klaus, Helmers, Henk, Donald, Royden, Kress, Hans-Georg, Adriaensen, Hugo, Moulin, Dwight, Järvimäki, Voitto, Haazen, Ludo
Format: Article
Language:English
Subjects:
chronic noncancer pain
efficacy
safety
Transdermal fentanyl
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this international, multicenter, open-label trial was to assess the efficacy and safety of up to 12 months of therapy with transdermal therapeutic system (TTS) fentanyl in patients (n = 532) with chronic noncancer pain. The trial was completed by 301 (57%) of the patients. The main outcome measures were pain control assessment, global treatment satisfaction, patient preference for TTS fentanyl, and quality of life. The mean dose of transdermal fentanyl (TDF) increased from 48 to 90 μg/h during a period of 12 months. During treatment, on average 67% of patients within the efficacy analysis group (n = 524) reported very good, good, or moderate pain control. Global satisfaction (very good or good) was also stable at 42%. The majority (86%) of patients reported a preference for TDF over their previous treatment (P
ISSN:1526-5900
1528-8447
DOI:10.1054/jpai.2001.25352